In 2006, the Integrated Benefits Institute pursued further research on how senior financial executives link health and productivity. In collaboration with CFO Research Services (a unit of CFO Publishing Corp.), IBI surveyed and analyzed results from 343 CFOs, financial directors, executive and senior vice presidents of finance and vice presidents of finance. The study was funded by Novartis, a member of the IBI Board of Directors.
Beginners Guide to TikTok for Search - Rachel Pearson - We are Tilt __ Bright...
The Business Value of Health: Linking CFOs To Health And Productivity
1. The Business Value of Health Linking CFOs to Health and Productivity IBI Research - 2006 IBI CFO Research Source: The Business Value of Health: Linking CFOs to Health and Productivity , Integrated Benefits Institute, 2006
2.
3. CFO Healthcare Management Objectives for Next Two Years No difference Source: The Business Value of Health: Linking CFOs to Health and Productivity , Integrated Benefits Institute, 2006
4. The Impact of Ill-Health 96% 90% 86% 84% 71% Source: The Business Value of Health: Linking CFOs to Health and Productivity , Integrated Benefits Institute, 2006
5.
6. Lost Work Time Criticality 49% Source: The Business Value of Health: Linking CFOs to Health and Productivity , Integrated Benefits Institute, 2006
7.
8. How CFOs Quantify Health-related Lost Productivity Source: The Business Value of Health: Linking CFOs to Health and Productivity , Integrated Benefits Institute, 2006
9. How CFOs Would Use Lost-Productivity Information Source: The Business Value of Health: Linking CFOs to Health and Productivity , Integrated Benefits Institute, 2006
Notas do Editor
In 2006, the Integrated Benefits Institute pursued further research on how senior financial executives link health and productivity. In collaboration with CFO Research Services (a unit of CFO Publishing Corp.), IBI surveyed and analyzed results from 343 CFOs, financial directors, executive and senior vice presidents of finance and vice presidents of finance. The study was funded by Novartis, a member of the IBI Board of Directors.